Pediatrix Medical Group (NYSE:MD) Raised to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Pediatrix Medical Group (NYSE:MD) from a buy rating to a strong-buy rating in a research note released on Saturday.

Several other equities analysts have also recently commented on MD. Weiss Ratings restated a “hold (c)” rating on shares of Pediatrix Medical Group in a research report on Saturday, September 27th. Leerink Partners lifted their price objective on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the company a “market perform” rating in a research note on Friday, September 5th. UBS Group upped their target price on Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a “neutral” rating in a research note on Thursday, August 14th. Finally, Zacks Research upgraded Pediatrix Medical Group to a “strong-buy” rating in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Pediatrix Medical Group presently has an average rating of “Hold” and a consensus price target of $16.79.

Pediatrix Medical Group Price Performance

Pediatrix Medical Group stock opened at $17.64 on Friday. The stock’s fifty day moving average price is $15.92 and its two-hundred day moving average price is $14.43. The firm has a market cap of $1.54 billion, a PE ratio of 13.67 and a beta of 1.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.80 and a quick ratio of 1.80. Pediatrix Medical Group has a one year low of $11.59 and a one year high of $17.77.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.11. The company had revenue of $468.84 million for the quarter, compared to analysts’ expectations of $464.37 million. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.Pediatrix Medical Group’s revenue was down 7.1% on a year-over-year basis. During the same quarter last year, the business earned $0.34 earnings per share. As a group, research analysts expect that Pediatrix Medical Group will post 1.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of hedge funds have recently modified their holdings of MD. GAMMA Investing LLC increased its holdings in Pediatrix Medical Group by 219.5% in the first quarter. GAMMA Investing LLC now owns 2,569 shares of the company’s stock valued at $37,000 after purchasing an additional 1,765 shares during the period. Marshall & Sullivan Inc. WA acquired a new stake in shares of Pediatrix Medical Group in the second quarter valued at about $41,000. Canada Pension Plan Investment Board bought a new position in shares of Pediatrix Medical Group during the second quarter worth about $83,000. AlphaQuest LLC lifted its stake in shares of Pediatrix Medical Group by 16.0% in the first quarter. AlphaQuest LLC now owns 5,877 shares of the company’s stock worth $85,000 after acquiring an additional 811 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Pediatrix Medical Group in the second quarter valued at approximately $99,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.